MP-201
Multiple Indications (Neurodegenerative)
PreclinicalActive
Key Facts
Indication
Multiple Indications (Neurodegenerative)
Phase
Preclinical
Status
Active
Company
About Mitochon Pharmaceuticals
Mitochon Pharmaceuticals is a private, clinical-stage biotech leveraging a platform of mitochondrial-targeting chemical uncouplers/ionophores to address a range of neurodegenerative diseases with high unmet need. The company's lead programs, MP-101 and MP-201, are backed by preclinical data demonstrating neuroprotection in models of ALS, Huntington's, Parkinson's, Alzheimer's, Multiple Sclerosis, and Traumatic Brain Injury. Led by a seasoned team with prior exit and NDA approval experience, Mitochon is pursuing a novel, upstream approach to disease modification but faces the inherent risks of early clinical development and platform validation.
View full company profileTherapeutic Areas
Other Multiple Indications (Neurodegenerative) Drugs
| Drug | Company | Phase |
|---|---|---|
| MP-101 | Mitochon Pharmaceuticals | Preclinical |